Assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers
Study identifier:D1120C00040
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects
Medical condition
Juvenile Idiopathic Arthritis
Phase
Phase 1
Healthy volunteers
Yes
Study drug
naproxen, esomeprazole
Sex
All
Actual Enrollment
28
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 May 2011
Primary Completion Date: 01 Jun 2011
Study Completion Date: 01 Jun 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Mark Sostek
AstraZeneca
